• The portfolio company Umecrine Cognition presented recent preclinical data showing that golexanolone reverses dopamine loss and sustains improvements of Parkinsonian symptoms at the 19th International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) 2025, in Vienna, Austria (April 2025).
• Karolinska Development announced that Viktor Drvota took over as CEO of the portfolio company Umecrine Cognition. Viktor Drvota remains the CEO of Karolinska Development (April 2025).
• The portfolio company OssDsign announced a change of CEO during the second half of 2025. The purpose is to support the establishment of leadership with an even stronger presence and focus on the US market (April 2025).
• The portfolio company Umecrine Cognition has been awarded a research grant by The Michael J. Fox Foundation (MJFF) amounting to USD 420,000. The grant will finance preclinical studies to evaluate the potential treatment effect of golexanolone in Parkinson’s disease (April 2025).
• The portfolio company Umecrine Cognition attended the EASL Congress 2025 in Amsterdam, May 7–10, presenting validation and implementation data for its newly developed clinical scale for Primary Biliary Cholangitis, PBC (May 2025).
• The portfolio company OssDsign reached a new milestone with 10,000 patients treated with its innovative nanosynthetic bone graft OssDsign Catalyst on the US market (May 2025).
• At Karolinska Development’s Annual General Meeting, it was decided, among other things, to adopt the profit and loss statement and the balance sheet as well as the consolidated profit and loss statement, the consolidated balance sheet, and to approve the allocation of the result, proposed by the Board of Directors and the CEO, to elect Anders Härfstrand to the Board of Directors and to re-elect Philip Duong, Anna Lefevre Skjöldebrand, Ben Toogood and Will Zeng to its Board of Directors, and to elect Ben Toogood Chairman of the Board (May 2025).
• The portfolio company Umecrine Cognition resumed the inclusion of patients to the clinical
  phase 1b/2a trial evaluating the drug candidate golexanolone in PBC patients. In March, Umecrine Cognition announced that the study had been halted due to technical issues in the production of capsules used in the study, which, however, had no impact on patient safety (May 2025).
• The portfolio company OssDsign has carried out a directed share issue through an accelerated bookbuilding procedure that brought the company approximately SEK 158 million. In connection with the directed share issue, the company announced an updated strategy and revised its financial targets for the period 2025–2028 (June 2025).
• The portfolio company Modus Therapeutics carries out a fully secured rights issue of units of SEK 28.3 million. The proceeds from the rights issue are intended to finance the continued development of the drug candidate sevuparin in chronic kidney disease with anemia (June 2025).
• Karolinska Development divested its remaining shares in the portfolio company OssDsign and thereby strengthened the investment company’s liquidity. The divestments provided Karolinska Development with a capital injection of approximately SEK 34.5 million (June 2025). 

Karolinska Development in Penserpoddens podcast Life Science-theme with exciting company pitches- 31 August 2023 (In Swedish)

Karolinska Development - Presentation Erik Penser Bank - 26 augusti 2021 (Video in Swedish)

OssDsign hissar flaggan i frankrike (In Swedish)

Tunga FDA-skalpar för Karolinska Developments portföljbolag Aprea (In Swedish)

Aprea uppnår positiva resultat mot svårfångad målmolekyl (In Swedish)

Karolinska Development-bolaget Forendo Pharma meddelar positiva fas Ia-resultat (In Swedish)

Karolinska Developments portföljbolag Umecrine Cognition levererade positiva säkerhetsdata från fas IIa-studie (In Swedish)